CD44 or its isoform has long been thought to be a marker CSC marker,[4, 46] however, controversy remains especially as to its correlation with clinical outcome.[39, 47] In addition, single‐cell cloning of colon CSCs revealed a multilineage differentiation capacity in tumorigenesis using CD44−/− mice model.[29] From the 10 × Genomics data with all cells, the population of EPC_A plus EPC_B are ≈2‐fold in tumor tissues than in the matched normal colon tissues, and about 40% EPCs in tumors were likely malignant cancer EPCs. Here, CD44 is linked to neoplasm.